Bioventus Q3 2026 Results: Net Income $5.99M, Up 89.8% YoY
Bioventus Inc. filed its Q3 2026 10-Q reporting on the period ended September 26, 2026, noting 68,474,219 shares of Class A common stock outstanding. The company is currently undergoing a strategic alternatives review process while managing risks related to debt covenants under its 2025 Credit Agreement and potential FDA reclassification of its HA products.
- Key figure
- Net income $5.99M · +89.8% YoY